<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04114357</url>
  </required_header>
  <id_info>
    <org_study_id>1907172784</org_study_id>
    <nct_id>NCT04114357</nct_id>
  </id_info>
  <brief_title>Effect of Prebiotics on the Gut Microbiome Profile and Beta Cell Function</brief_title>
  <official_title>Evaluating the Effect of Prebiotics on the Gut Microbiome Profile and Beta Cell Function in Newly Diagnosed Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data suggest that intestinal microbiota might be critically involved both in autoimmunity and&#xD;
      in glucose homeostasis. An acetylated and butyrylated form of high amylose maize starch&#xD;
      (HAMS-AB) that increases beneficial short chain fatty acid (SCFA) production has been safe&#xD;
      and effective in disease prevention in mouse type 1 diabetes (T1D) models. The objective of&#xD;
      this application is to assess the effect of administering a prebiotic, such as HAMS- AB, on&#xD;
      the gut microbiome profile, glycemia and β-cell function in humans with T1D.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot, single center clinical trial to evaluate the effect of using the prebiotic,&#xD;
      HAMS-AB, on the gut microbiome profile, glycemia and β-cell function in children and&#xD;
      adolescents ages 12-16 years with recently diagnosed type 1 diabetes.&#xD;
&#xD;
      Approximately 12 participants will be randomized first to take the supplement or follow a&#xD;
      diabetic diet for 4 weeks and then cross-over after a 4 week washout period.&#xD;
&#xD;
      The primary objective is to determine the effect of using the prebiotic on the gut microbiome&#xD;
      profile in youth with T1D.&#xD;
&#xD;
      The secondary objectives are to determine the effect of using the prebiotic on SCFA&#xD;
      production, glycemia and β-cell health and function&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the gut microbiome profile</measure>
    <time_frame>Through study completion, an average of 12 weeks</time_frame>
    <description>We plan to assess the effect of administering HAMS-AB on the gut microbiome profile in people with recently-diagnosed T1D by sequencing the gut microbiome profile.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the Short Chain Fatty Acid Levels in the Gut.</measure>
    <time_frame>Through study completion, an average of 12 weeks</time_frame>
    <description>Measurement of Short Chain Fatty Acid Levels in the Stools.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Glycemia.</measure>
    <time_frame>Through study completion, an average of 12 weeks</time_frame>
    <description>We will compare glycemic changes pre/post intervention with HAMS-AB and between the intervention and control groups. We will measure glycemia using HbA1c, average glucose and glucose variability using blinded continuous glucose monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Beta cell Health.</measure>
    <time_frame>Through study completion, an average of 12 weeks</time_frame>
    <description>We will compare β-cell measures pre/post intervention with HAMS-AB and between the intervention and control groups. We will assess β-cell function using mixed meal tolerance-derived C-peptide measures. We will assess β-cell stress using fasting proinsulin/C-peptide (PI:C) ratios. We will assess β-cell death by differential methylation of preproinsulin (INS) DNA.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will consume the supplement daily for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm will not receive the supplement for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylated and Butyrylated High Amylose Maize Starch</intervention_name>
    <description>Participants will be instructed to consume HAMS-AB in two divided doses at breakfast and dinner</description>
    <arm_group_label>Intervention Group</arm_group_label>
    <other_name>Hylon™ VII Butyrate, Hylon™ VII Acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be between 12-16 years of age&#xD;
&#xD;
          -  Willing to consume HAMS-AB and follow a diabetic diet&#xD;
&#xD;
          -  Diagnosed by American Diabetes Association criteria with T1D in the last 4-24 months&#xD;
&#xD;
          -  Random non-fasting C-peptide of 0.17nmol/ml or greater&#xD;
&#xD;
          -  Willing to use an effective form of contraception if sexually active&#xD;
&#xD;
          -  BMI&lt; 85% for age and sex&#xD;
&#xD;
          -  Positive for any one of the following diabetes-related autoantibodies that are tested&#xD;
             clinically [insulin autoantibody (if tested within 14 days of diagnosis), glutamic&#xD;
             acid decarboxylase (GAD), insulinoma-associated protein-2 (IA-2), or Zinc transporter&#xD;
             8 autoantibodies (ZnT8)].&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of severe, active disease that interferes with dietary intake or requires the&#xD;
             use of chronic medication, except for well-controlled hypothyroidism and mild asthma&#xD;
             not requiring oral steroids.&#xD;
&#xD;
          2. Diabetes other than T1D (Known monogenic forms of diabetes, Type 2 diabetes)&#xD;
&#xD;
          3. Chronic illness known to affect glucose metabolism (e.g. Cushing syndrome, polycystic&#xD;
             ovarian disorder, cystic fibrosis) or taking medications that affect glucose&#xD;
             metabolism (e.g. steroids, metformin)&#xD;
&#xD;
          4. Psychiatric impairment or current use of anti-psychotic medication&#xD;
&#xD;
          5. Any condition that, in the investigator's opinion, may compromise study participation&#xD;
             or may confound the interpretation of the study results.&#xD;
&#xD;
          6. Female participants of child-bearing age with reproductive potential, must not be&#xD;
             pregnant and agree to use an effective form of birth control or be abstinent during&#xD;
             the study period (see below)&#xD;
&#xD;
          7. History of recurrent infections&#xD;
&#xD;
          8. History of on-going infections or antibiotic treatment within the past three months&#xD;
&#xD;
          9. History of immune compromise&#xD;
&#xD;
         10. Steroid intake (inhaled or oral)&#xD;
&#xD;
         11. Other immunosuppressant use in past 6 months&#xD;
&#xD;
         12. History of gastrointestinal disease&#xD;
&#xD;
         13. Possible or confirmed celiac disease&#xD;
&#xD;
         14. Pregnancy or possible pregnancy&#xD;
&#xD;
         15. Allergy to corn (prebiotic)&#xD;
&#xD;
         16. Allergy to milk or milk products or soy present in Boost&#xD;
&#xD;
         17. Participation in other intervention research trials within the past 3 months&#xD;
&#xD;
         18. Anticipate major changes in diabetes management during study (change from injection to&#xD;
             pump, new start of continuous glucose monitoring)&#xD;
&#xD;
         19. Consuming high fiber or vegetarian diet (consuming three or more servings of high&#xD;
             fiber foods on 4 or more days per week) using validated dietary assessments (see below&#xD;
             under schedule of events table).&#xD;
&#xD;
         20. Taking fiber supplements&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Heba Ismail, MD</last_name>
    <phone>317-278-7856</phone>
    <email>heismail@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tiffany Lewallen</last_name>
    <phone>317-278-7856</phone>
    <email>tlewalle@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heba Ismail</last_name>
      <phone>317-278-7856</phone>
      <email>heismail@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jillian Kapturowski</last_name>
      <phone>317-278-7042</phone>
      <email>jkapturo@iu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Heba M. Ismail</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

